CL2017002904A1 - Métodos y kits para tratar la depresión - Google Patents

Métodos y kits para tratar la depresión

Info

Publication number
CL2017002904A1
CL2017002904A1 CL2017002904A CL2017002904A CL2017002904A1 CL 2017002904 A1 CL2017002904 A1 CL 2017002904A1 CL 2017002904 A CL2017002904 A CL 2017002904A CL 2017002904 A CL2017002904 A CL 2017002904A CL 2017002904 A1 CL2017002904 A1 CL 2017002904A1
Authority
CL
Chile
Prior art keywords
kits
methods
treatment
depression
treat depression
Prior art date
Application number
CL2017002904A
Other languages
English (en)
Inventor
Jaskaran Singh
Ivo Caers
Ella Daly
Wayne C Drevets
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CL2017002904A1 publication Critical patent/CL2017002904A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Treatments Of Macromolecular Shaped Articles (AREA)
  • Steroid Compounds (AREA)
  • Emergency Medicine (AREA)

Abstract

<p>La presente invención está dirigida a, entre otras cosas, métodos y kits para el tratamiento de la depresión (preferentemente, depresión resistente al tratamiento), o para el tratamiento de la depresión en un paciente suicida y/o para el tratamiento y/o prevención de suicidios (por ejemplo, pensamientos suicidas) que incluyen la administración de esketamina de conformidad con ciertos regímenes de dosis.</p>
CL2017002904A 2015-05-20 2017-11-15 Métodos y kits para tratar la depresión CL2017002904A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562164026P 2015-05-20 2015-05-20

Publications (1)

Publication Number Publication Date
CL2017002904A1 true CL2017002904A1 (es) 2018-04-20

Family

ID=57320901

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017002904A CL2017002904A1 (es) 2015-05-20 2017-11-15 Métodos y kits para tratar la depresión

Country Status (20)

Country Link
US (1) US20160338977A1 (es)
EP (1) EP3297618A4 (es)
JP (1) JP2018515557A (es)
KR (1) KR20180008634A (es)
CN (1) CN107735081A (es)
AU (3) AU2016263598A1 (es)
CA (1) CA2986477A1 (es)
CL (1) CL2017002904A1 (es)
CO (1) CO2017011564A2 (es)
DO (1) DOP2017000268A (es)
EA (1) EA201792545A1 (es)
EC (1) ECSP17077930A (es)
GT (1) GT201700246A (es)
HK (1) HK1252937A1 (es)
IL (1) IL255463A (es)
MA (1) MA42135A (es)
MX (1) MX2017014797A (es)
PE (1) PE20180260A1 (es)
PH (1) PH12017502103A1 (es)
WO (1) WO2016187491A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140275278A1 (en) 2013-03-15 2014-09-18 Janssen Pharmaceutica Nv Pharmaceutical composition of s-ketamine hydrochloride
EP3179993B1 (en) 2014-08-13 2021-01-20 Janssen Pharmaceutica NV Esketamine for use in a method for the treatment of depression
CA2961208A1 (en) 2014-09-15 2016-03-24 Janssen Pharmaceutica Nv Val66met (snp rs6265) genotype specific dosing regimens and methods for the treatment of depression
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
AU2016288188B2 (en) 2015-06-27 2021-08-05 Shenox Pharmaceuticals, Llc Ketamine transdermal delivery system
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
MX2020006650A (es) * 2017-12-22 2020-11-06 Janssen Pharmaceuticals Inc Esketamina para el tratamiento de la depresión.
PL3505157T3 (pl) 2017-12-29 2022-04-11 Celon Pharma S.A. Kompozycja ketaminy w postaci suchego proszku do podawania dopłucnego w leczeniu depresji opornej na leczenie
BR112020023882A2 (pt) * 2018-06-27 2021-02-09 Clexio Biosciences Ltd. método para tratar transtorno depressivo maior
EP3628313B1 (en) * 2018-09-28 2025-02-12 Novohale Therapeutics, LLC Ketamine composition for use in a method of treatment of depression by pulmonary administration
WO2020070547A1 (en) * 2018-10-05 2020-04-09 Clexio Biosciences Ltd. Dosage regime of esketamine for treating major depressive disorder
US11865088B2 (en) * 2018-10-05 2024-01-09 Clexio Biosciences Ltd. Method of treating major depressive disorder
EP3863617A1 (en) 2018-10-11 2021-08-18 Clexio Biosciences Ltd. Esketamine for use in treating major depressive disorder
WO2020178653A1 (en) * 2019-03-05 2020-09-10 Janssen Pharmaceuticals, Inc. Esketamine for the treatment of depression
JP2022546456A (ja) * 2019-08-28 2022-11-04 ヤンセン ファーマシューティカルズ，インコーポレーテッド 自殺傾向を含む大うつ病性障害を有する患者の治療のためのエスケタミン
TW202135787A (zh) 2019-12-12 2021-10-01 比利時商健生藥品公司 艾氯胺酮調配物及製備與儲存的方法
US12268658B2 (en) 2019-12-30 2025-04-08 Clexio Biosciences Ltd. Dosage regime with esketamine for treating major depressive disorder
US12478592B2 (en) 2019-12-30 2025-11-25 Clexio Biosciences Ltd. Dosage regime with esketamine for treating neuropsychiatric or neurological conditions
CN115768519A (zh) * 2020-05-28 2023-03-07 詹森药业有限公司 治疗抑郁症的方法
GB202019952D0 (en) * 2020-12-17 2021-02-03 Neurocentrx Pharma Ltd Novel compositions
WO2022235576A1 (en) * 2021-05-03 2022-11-10 Wang Michael Z Methods and compositions for treating depression

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101466364A (zh) * 2006-03-22 2009-06-24 纽约大学西奈山医学院 鼻内施用氯胺酮治疗抑郁症
US20110038807A1 (en) * 2009-08-14 2011-02-17 Demitri Papolos Compositions and methods for treating bipolar disorder
US9073819B2 (en) * 2011-06-30 2015-07-07 University Of South Florida Compositions, methods of use, and methods of treatment
WO2013138322A1 (en) * 2012-03-12 2013-09-19 Janssen Pharmaceutica Nv Esketamine for the treatment of treatment-refractory or treatment-resistant depression
JP2015512418A (ja) * 2012-03-30 2015-04-27 ザ ジェネラル ホスピタル コーポレイション うつ病の治療におけるスコポラミンおよびケタミンを含む組成物
AU2014250756B2 (en) * 2013-04-12 2019-03-07 Icahn School Of Medicine At Mount Sinai Method for treating post-traumatic stress disorder
CA2961208A1 (en) * 2014-09-15 2016-03-24 Janssen Pharmaceutica Nv Val66met (snp rs6265) genotype specific dosing regimens and methods for the treatment of depression

Also Published As

Publication number Publication date
KR20180008634A (ko) 2018-01-24
ECSP17077930A (es) 2018-02-28
CA2986477A1 (en) 2016-11-24
AU2016263598A8 (en) 2017-11-30
AU2023237026A1 (en) 2023-10-12
EP3297618A4 (en) 2019-01-23
US20160338977A1 (en) 2016-11-24
WO2016187491A1 (en) 2016-11-24
EA201792545A1 (ru) 2018-05-31
MA42135A (fr) 2018-03-28
CO2017011564A2 (es) 2018-04-19
DOP2017000268A (es) 2018-04-15
GT201700246A (es) 2019-07-29
CN107735081A (zh) 2018-02-23
AU2021215155A1 (en) 2021-09-02
JP2018515557A (ja) 2018-06-14
MX2017014797A (es) 2018-02-15
EP3297618A1 (en) 2018-03-28
IL255463A (en) 2018-01-31
PH12017502103A1 (en) 2018-05-07
AU2016263598A1 (en) 2017-11-23
HK1252937A1 (zh) 2019-06-06
PE20180260A1 (es) 2018-02-05

Similar Documents

Publication Publication Date Title
DOP2017000268A (es) Metodos y kits para tratar depresion
CL2018003588A1 (es) Uso de inhibidores de miostatina y terapias de combinación.
DOP2019000180A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
CL2018003213A1 (es) Inhibidores enzimáticos.
CL2017003006A1 (es) Métodos de acondicionamiento de pacientes para tratamiento con linfocitos t
MX2019009853A (es) Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres.
CL2017003005A1 (es) Métodos de diagnóstico para tratamiento con linfocitos t
MX2021013830A (es) Inhibidores de ezh2 para tratar linfomas.
CO2017001493A2 (es) Kits que comprenden inhibidores tigit y agentes anticáncer
MX2017007256A (es) Inhibidor de bromodominio como adyuvante en la inmunoterapia contra el cancer.
AR101312A1 (es) Combinaciones de inhibidores de bet e inhibidores de tirosina quinasa de bruton
MX2020004837A (es) Inhibidores de la vía de adenosina para el tratamiento del cáncer.
BR112018008882A8 (pt) método para tratar um distúrbio proliferativo e produto farmacêutico
BR112015018360A2 (pt) terapia de combinação para o tratamento de pneumonia nosocomial
BR112019003533A2 (pt) terapia de combinação com inibidores de glutaminase
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
MX2023007405A (es) Regimen de cladribina para usarse en el tratamiento de formas progresivas de esclerosis multiple.
BR112018003836A2 (pt) combinações de inibidor de btk para tratar mieloma múltiplo
MX2021003263A (es) Combinacion de un antagonista de proteina de muerte programada 1 (pd-1), un inhibidor de ataxia telangiectasia y proteina relacionada con rad3 (atr) y un agente de platino para el tratamiento de cancer.
CO2017002356A2 (es) Métodos para tratar la depresión usando moduladores de nmda
BR112017014914A2 (pt) terapia combinada para hipertensão pulmonar
AR105701A1 (es) Métodos y estuches para tratar la depresión
MX2020004731A (es) Terapias de combinacion de inhibidor ezh2.
AR109858A1 (es) Métodos que usan inhibidores hdac11